DEALTALK-AstraZeneca not only game in town for deal-hungry Pfizer
(For more Reuters DEALTALKS, double click on )
* Pfizer reviewing takeover scenarios beyond Astra -sources
* Chance of U.S. firm renewing Astra pursuit seen receding
* Enforced cooling-off period ends on Nov. 26
* Pfizer taking close look at Actavis as target -sources
By Pamela Barbaglia and Sophie Sassard
LONDON, Nov 14 (Reuters) - Pfizer appears unlikely to make a fresh bid for AstraZeneca in 12 days time, when an enforced cooling-off period ends, and the U.S. drugmaker is now weighing other less risky targets.
People with direct knowledge of the situation said Pfizer has been reviewing different takeover scenarios with a U.S. investment bank ahead of Nov. 26, when it is allowed to renew its pursuit of AstraZeneca under UK takeover rules.
This includes a close analysis of the benefits of a tax-saving deal to buy Dublin-based generic drugmaker Actavis , which has a market value of around $64 billion against AstraZeneca's $94 billion. Continued...